title: Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma.
abstract: BACKGROUND
  Thyroglobulin (Tg) measurement following thyrotropin (TSH) stimulation is used in the follow-up of patients with differentiated thyroid carcinoma (DTC). However, high-sensitive assays allow accurate measurement of serum Tg even without TSH stimulation. Here, we prospectively evaluated the impact of unstimulated high-sensitive Tg measurement in early and long-term outcome of patients with DTC.
  
  
  METHODS
  One hundred and ninety five patients affected with DTC were evaluated. Six months after thyroid ablation (i.e., thyroidectomy plus radioiodine) serum Tg was measured during TSH-suppressive thyroxine (T4) treatment (onT4-Tg). Patients with undetectable onT4-Tg and negative neck ultrasound (US) were considered disease free and onT4-Tg was measured every 12 months for a mean follow-up of 6.8 (4.7-8.9) years. Patients with an increase in onT4-Tg underwent specific diagnostic work-up and appropriate treatment if necessary.
  
  
  RESULTS
  Four patients showed recurrence at first follow-up visit with a corresponding increase in onT4-Tg concentrations (sensitivity 100%). Three patients had false positive onT4-Tg measurement (specificity 98%) with a spontaneous decrease within 3-6 months in all cases (specificity 100%). Three of 188 patients with undetectable serum onT4-Tg at first follow-up showed recurrence later with an increase in onT4-Tg as the first (n=2) or unique (n=1) sign of relapse (sensitivity 100%). Among 185 disease-free patients in a prolonged follow-up, 12 had a transient increase in onT4-Tg (specificity 91.6%). However, a spontaneous reduction within 3-6 months occurred in all cases (specificity 100%).
  
  
  CONCLUSIONS
  Undetectable serum onT4-Tg using a high-sensitivity immunoradiometric assay 6 months after thyroid ablation predicts low-risk of DTC recurrence. When onT4-Tg became detectable during follow-up, the evaluation of Tg slope in a 3-6 months period accurately discriminated patients with DTC recurrence from those without recurrence. This helped avoid unnecessary diagnostic or therapeutic procedures.
authors: Department of Nuclear Medicine, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. luca.giovanella@eoc.ch
authors: Luca
authors: L
authors: Giovanella
authors: Marco
authors: M
authors: Maffioli
authors: Luca
authors: L
authors: Ceriani
authors: Diego
authors: D
authors: De Palma
authors: Giuseppe
authors: G
authors: Spriano
mesh_terms: D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000097:blood* / Q000532:radiotherapy / Q000601:surgery; D005260:Female; D006801:Humans; D015592:Immunoradiometric Assay; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000175:diagnosis*; D011446:Prospective Studies; D013954:Thyroglobulin / Q000097:blood*; D013964:Thyroid Neoplasms / Q000097:blood* / Q000532:radiotherapy / Q000601:surgery; D013972:Thyrotropin / Q000008:administration & dosage; D013974:Thyroxine / Q000627:therapeutic use
chemical_list: D013972:Thyrotropin; D013954:Thyroglobulin; D013974:Thyroxine